BioSig Technology BSGM shares are trading higher on Friday after the company's subsidiary VirtalClear submitted an investigational new drug application to the FDA for a Phase 2 clinical trial of Merimepodib.
BioSig Technologies is a medical technology company developing a proprietary biomedical signal processing platform designed to improve the electrophysiology marketplace.
BioSig Technology shares were trading up 10.51% at $8.52 on Friday. The stock has a 52-week range between $9.97 and $2.36.
Related Link: Why Aptevo Therapeutics Is Trading Higher Today
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
